Abstract
Introduction of aortocoronary bypass at the end of the 1960s, coronary angioplasty in 1977, and coronary stents in 1987 and stents covered by antiproliferation substances sirolime and paklitaxel (Drug Eluting Stent - DES) in recent years mean a great progress in treatment of coronary diseases. Coronary stents improved in most patients the results of coronary angioplasty, and the coated stents markedly reduced restenosis, which has not confirmed the previous fears of a rise in early or subacute thrombotic closures of these coated stents.
Their use in various institutions in the world varies between 5 % and 100 %. Millions of uncoated stents (BMS - Bare Metal Stents) and DES are implanted worldwide, in the CR about 20,000 coronary stents, of which 5-15 % a year are DES.
Some recent news about the risk of late thrombotic closures of the stents, especially DES with high mortality with this complication (20 ? 50 %), is therefore bothersome.